Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Clinical outcomes in spliceosome-mutant myelodysplastic neoplasms and Acute Myeloid Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

SPShyam A. Patel

Discussion

Loading...

Member takes

Overview

Observational analysis reveals spliceosome mutations influence treatment modality outcomes in myelodysplastic neoplasms and leukemia.

Key Points

  • This research aims to evaluate how different spliceosome mutations affect survival outcomes in MDS and AML.
  • Conducted an observational study of 97 patients with spliceosome gene mutations
  • Collected clinical data on demographics, treatment types, and outcomes
  • Analyzed outcomes based on treatment type and time-to-event endpoints
  • 97 patients were analyzed with a median overall survival of 29 months
  • Patients with U2AF1 mutation had a median OS of 15 months; SF3B1 mutations had an OS of 52 months
  • No significant survival differences were seen based on treatment types or mutational subtypes

Cite This Study

Shyam A. Patel (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d2bahttps://doi.org/10.1182/blood-2025-7038
View Full Paper
Ask AI
Bookmark
Share